No Data
Buy Rating Affirmed for Gain Therapeutics Amidst Promising Clinical Trials and Strong Financial Health
Buy Rating Affirmed for Gain Therapeutics Amid Positive Clinical and Financial Performance
Gain Therapeutics | 10-Q: Quarterly report
Gain Therapeutics' Q1 Cash, Cash Equivalent And Marketable Securities Were $12.7M, With Cash Runway Guidance Into 2025
Gain Therapeutics' Q1 Cash, Cash Equivalent And Marketable Securities Were $12.7M, With Cash Runway Guidance Into 2025
Gain Therapeutics 1Q Loss/Shr 22c >GANX
Gain Therapeutics 1Q Loss/Shr 22c >GANX
Buy Rating Affirmed for Gain Therapeutics on Promising GT-02287 Clinical Progress